THE 3 -methylchloanthrene -induced murine sarcoma, Meth A, is amongst the most strongly immunogenic of the chemically induced experimental tumours, so that it has been widely used as a model for the study of immune rejection responses and for the isolation and characterization of tumour-associated antigens (Law & Appella, 1975; Law et al., 1978) . Purified plasma-membrane preparations have frequently been used as a source of immunogenic material (McCollester, 1970; Natori et al., 1977) though more recently the soluble intracytoplasmic protein fraction of tumour homogenates was found to be a source of abundant antigen (Dubois et al., 1980) . Previous studies have demonstrated that the protein-cross-linking agent, glutaraldehyde, fails to modify the immunogenicity of Meth A sarcoma cells (Price et al., 1979) Avrameas et al., 1978) but below that used for the preparation of insoluble polymerized protein gels (Ternynk & Avrameas, 1976) . This concentration is also commonly used for the fixation of cells to be used in radioisotopic antiglobulin assays, with the retention of activity of serologically defined cellsurface antigens (Al-Sheikly et al., 1980) . As shown in the Table) . For example, the tumour t Immunizing fractions were treated with 0-01 % glutaraldehyde for 30 min, after which membrane preparations, cells and nuclei were washed by centrifugation and resuspended in PBS, whilst the treated cytosol was dialysed against PBS at 4°C. Rogers et al. (1980) . Prepared according to Price & Baldwin (1974 The present findings are in accord with the current view that the Meth A sarcomaassociated rejection antigen is a soluble protein which is expressed intracellularly (Dubois et al., 1980) . The antigen must show some expression at the cell surface, to initiate immune responses and to function as a target for immunological recognition and attack, though how many determinants are required to participate in such reactions is unknown. It is possible that only a few copies at the cell surface are sufficient, and/or that their expression at the surface is transient, occurring only during export and secretion. If the antigen is in fact secreted, then it is rapidly inactivated, since soluble ascitic fluid and tumour-bearer serum were clearly nonimmunogenic in the present investigation (Expt 7). The finding that Meth A nuclei were immunogenic is open to several interpretations. Is the Meth A antigen expressed on nuclei or on nuclear membranes? Alternatively, does their immunogenicity reflect adsorption of soluble cytoplasmic antigen? The present results emphasize that there is a need for caution in interpreting data in terms of antigen localization following subcellular fractionation of tumour homogenates.
The stability and resistance of the Meth A antigen to glutaraldehyde is remarkable. The results do not support the contention that the immunogenicity of treated cells is attributable to the slow release of nonfixed soluble cytoplasmic antigen. Vigorous extraction of fixed cells or direct treatment of plasma membranes or cytosol does not modify the immunogenic character of these preparations, suggesting that glutaraldehyde-treated antigen per se is immunogenic, and that host processing leading to the induction of immunity is not impaired by the presentation of antigen chemically modified with glutaraldehyde. Further studies are required to determine how, in the induction of immunity to the Meth A sarcoma, the immunized host may process the antigen when it is presented on a highly polymerized substrate (e.g. the treated cell).
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